A Comprehensive Monograph on Lobeglitazone (DB09198): Pharmacology, Clinical Profile, and Comparative Analysis

Section 1: Drug Identification and Physicochemical Properties

1.1. Nomenclature and Identifiers

Lobeglitazone is a small molecule antidiabetic agent identified by a comprehensive set of chemical, commercial, and regulatory identifiers to ensure unambiguous reference across scientific literature, clinical practice, and regulatory documentation.

Its non-proprietary, or generic, name is Lobeglitazone.[1] The compound is systematically named according to the International Union of Pure and Applied Chemistry (IUPAC) nomenclature as 5-[[2-[[6-(4-methoxyphenoxy)pyrimidin-4-yl]-methylamino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione.[2]

During its development by Chong Kun Dang Pharmaceutical Corp., it was referred to by the code CKD-501 (also documented as CKD 501 and CKD501).[1] Upon receiving marketing authorization, it has been commercialized under distinct brand names in approved regions: Duvie in South Korea and LOBG in India.[3]

To facilitate its identification in global databases and regulatory systems, Lobeglitazone is assigned several standard identifiers. These include its DrugBank accession number DB09198 and its Chemical Abstracts Service (CAS) Registry Number, which is 607723-33-1 for the free base form of the molecule.[2] The commonly used sulfate salt is identified by CAS number 763108-62-9.[5] Other key identifiers are summarized in the table below.

1.2. Chemical Structure and Properties

Lobeglitazone is an aromatic ether belonging to the thiazolidinedione (TZD) class of compounds.[7] Its molecular structure is defined by the chemical formula , corresponding to a molecular weight of approximately 480.54 g/mol for the free base.[1] The sulfate salt has the formula  and a molecular weight of 578.62 g/mol.[6]